Geriatric assessments and frailty scores in multiple myeloma patients: a needed tool for individualized treatment?. Issue 6 (16th November 2021)

• Record Type: Journal Article
• Authors: Möller, Mandy-Deborah; Gengenbach, Laura; Graziani, Giulia; Greil, Christine; Wäsch, Ralph; Engelhardt, Monika
• Is Part Of: Current opinion in oncology. Volume 33:Issue 6(2021)
• Page Start: 648
• Page End: 657
• Publication Date: 2021-11-16
• Subjects: fitness -- frailty scores/functional geriatric assessment -- multiple myeloma; Oncology -- Periodicals; 616.994
• DOI: 10.1097/CCO.0000000000000792
• Languages: English
• ISSNs: 1040-8746

Abstract

Abstract : Purpose of review: Multiple myeloma is a disease of elderly adults. Improvement in survival has occurred because of biological insights and novel agents. Therapeutic options involve choices today, thus have become more complex. Demographics have led to an increased number of elderly patients and age may be associated with a poorer outcome but is not the only prognostic predictor today. Recent findings: To evaluate patients' health status rather than their chronological age alone, frailty scores and functional geriatric assessments are used to identify prognostic groups, avoid adverse events, compare clinical trials and tailor treatment. As most clinical trials exclude frail elderly patients, those enrolled therein are often younger and healthier than the typical multiple myeloma patient. This represents a challenge for frail cohorts because of their increased risk of adverse events, overtreatment and undertreatment and/or therapy discontinuation, which may lead to poorer survival and quality of life (QoL). Reassessing patients' status via geriatric assessments is also relevant during treatment to adjust interventions appropriately. Summary: Integrating geriatric assessments may lead to individual treatment decisions, dose adjustments, better clinical outcome and QoL. Prospective clinical trials that enroll elderly multiple myeloma patients with comorbidities, incorporate frailty scores/geriatric assessments and help with prognostication, adverse event avoidance and QoL maintenance, remain warranted.